While COVID-19 is widely known as a respiratory illness, its roster of mysterious symptoms is pointing researchers to a surprising possibility—what if COVID-19 only begins as a respiratory infection, but ultimately becomes one that infects the blood vessels?
A Lancet paper published in April found that SARS-CoV-2 can launch vicious attacks on the lining of blood vessels.
Every 2 weeks, Medical News Today rounds up the latest research results that may offer hope among the turmoil that is the COVID-19 pandemic. In our previous Special Feature, we looked at vaccine trials and antibody tests.
In this article, we cover the latest scientific discoveries, from antibodies and testing to drug candidates and potential treatments.
Demand for propofol—the ubiquitous intravenous anesthetic—has skyrocketed since the drug became key to ventilating ICU patients with COVID-19.
But hospitals have seen stressful shortages.
An investigation tracking propofol’s notoriously opaque journey from production to patient care underscores the vulnerabilities of a supply chain that relies on a few countries for production—and now faces a global crisis.
By mapping interactions between human proteins and the new coronavirus, researchers have pinpointed 29 potential treatments using drugs already approved by the Food and Drug Administration (FDA) for a wide range of other conditions.
There is currently no vaccine or antiviral drug with proven efficacy against SARS-CoV-2, the virus that causes COVID-19, though several clinical trials are underway.
Lack of in-depth knowledge about how the newly emerged virus interacts with human cells has hampered the hunt for an effective treatment.
A summary of the evidence so far suggests that obesity is associated with a higher risk of developing severe symptoms and complications of coronavirus disease 19 (COVID-19), independent of other illnesses, such as cardiovascular disease.
Early data seems to suggest that people with obesity are more likely to become severely ill due to COVID-19, the disease caused by the novel coronavirus.
An increasing number of reports have linked obesity to coronavirus mortality, and the Centers for Disease Control and Prevention (CDC) now list severe obesity as a risk factor for severe COVID-19. The CDC define severe obesity as having a body mass index (BMI) of 40 or above.
With the FDA approving Gilead’s Remdesivir as an emergency use treatment for the most acute cases of COVID-19, many people are wondering what type of a drug it is.
Remdesivir is a member of one of the oldest and most important classes of drugs – known as nucleoside analogue. Currently there are more than 30 of these types of drugs that have been approved for use in treating viruses, cancers, parasites, as well as bacterial and fungal infections, with many more currently in clinical and preclinical trials.